This site is intended for US healthcare professionals

This site is intended for US healthcare professionals

(not actual patient)

BeizrayTM is the first and only FDA approved docetaxel injection to be mixed with albumin before administration

(not actual patient)

Beizray is a microtubule inhibitor indicated for:

  • Breast Cancer (BC)

    Single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC1

  • Non-small Cell Lung Cancer (NSCLC)

    Single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC1

  • Castration-Resistant Prostate Cancer (CRPC)

    With prednisone in metastatic castration-resistant prostate cancer1

  • Gastric Adenocarcinoma (GC)

    With cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction1

  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)

    With cisplatin and fluorouracil for induction treatment of locally advanced SCCHN1

Beizray is supplied as a docetaxel + albumin kit and also supplied as single-dose vials1

NDC 70710-2093-4

BEIZRAY 160 mg kit1

Consisting of the following:

  • Two single-dose vials of BEIZRAY:
    80 mg/4 mL each; a clear and colorless liquid
  • One single-dose vial of IV Solution Stabilizer:
    50 mL of 25% Albumin Human USP solution for infusion; a clear and slightly viscous solution
NDC 70710-2091-3

BEIZRAY 80 mg kit1

Consisting of the following:

  • One single-dose vial of BEIZRAY:
    80 mg/4 mL; a clear and colorless liquid
  • One single-dose vial of IV Solution Stabilizer:
    50 mL of 25% Albumin Human USP solution for infusion; a clear and slightly viscous solution
NDC 70710-2092-8

BEIZRAY 20 mg/mL vial1

Consisting of the following:

  • One single-dose vial of BEIZRAY:
    20 mg/mL; a clear and colorless liquid

Beizray 80 mg/4 mL single-dose vial not available in the US

Permanent J code:

J9174
Order now

INDICATIONS AND IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING

WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID
RETENTION

  • Treatment-related mortality associated with BEIZRAY is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive BEIZRAY as a single agent at a dose of 100 mg/m2.
  • Avoid the use of BEIZRAY in patients with bilirubin > upper limit of normal (ULN), or to patients with AST and/or ALT >1.5 x ULN concomitant with alkaline phosphatase >2.5 x ULN.Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of severe neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death.Patients with isolated elevations of transaminase >1.5 x ULN also had a higher rate of febrile neutropenia.Measure bilirubin, AST or ALT, and alkaline phosphatase prior to each cycle of BEIZRAY.
  • Do not administer BEIZRAY to patients with neutrophil counts of <1500 cells/mm3. Monitor blood counts frequently as neutropenia may be severe and result in infection.
  • Do not administer BEIZRAY to patients who have a history of severe hypersensitivity reactions to BEIZRAY.Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. Hypersensitivity reactions require immediate discontinuation of the BEIZRAY infusion and administration of appropriate therapy.
  • Severe fluid retention occurred in 6.5% (6/92) of patients despite use of dexamethasone premedication. It was characterized by one or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites).
Image